Bretones Gabriel, Delgado M Dolores, León Javier
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-Universidad de Cantabria-SODERCAN and Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.
Instituto de Biomedicina y Biotecnología de Cantabria (IBBTEC), CSIC-Universidad de Cantabria-SODERCAN and Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain.
Biochim Biophys Acta. 2015 May;1849(5):506-16. doi: 10.1016/j.bbagrm.2014.03.013. Epub 2014 Apr 1.
Soon after the discovery of the Myc gene (c-Myc), it became clear that Myc expression levels tightly correlate to cell proliferation. The entry in cell cycle of quiescent cells upon Myc enforced expression has been described in many models. Also, the downregulation or inactivation of Myc results in the impairment of cell cycle progression. Given the frequent deregulation of Myc oncogene in human cancer it is important to dissect out the mechanisms underlying the role of Myc on cell cycle control. Several parallel mechanisms account for Myc-mediated stimulation of the cell cycle. First, most of the critical positive cell cycle regulators are encoded by genes induced by Myc. These Myc target genes include Cdks, cyclins and E2F transcription factors. Apart from its direct effects on the transcription, Myc is able to hyperactivate cyclin/Cdk complexes through the induction of Cdk activating kinase (CAK) and Cdc25 phosphatases. Moreover, Myc antagonizes the activity of cell cycle inhibitors as p21 and p27 through different mechanisms. Thus, Myc is able to block p21 transcription or to induce Skp2, a protein involved in p27 degradation. Finally, Myc induces DNA replication by binding to replication origins and by upregulating genes encoding proteins required for replication initiation. Myc also regulates genes involved in the mitotic control. A promising approach to treat tumors with deregulated Myc is the synthetic lethality based on the inhibition of Cdks. Thus, the knowledge of the Myc-dependent cell cycle regulatory mechanisms will help to discover new therapeutic approaches directed against malignancies with deregulated Myc. This article is part of a Special Issue entitled: Myc proteins in cell biology and pathology.
Myc基因(c-Myc)被发现后不久,人们就清楚地认识到Myc的表达水平与细胞增殖密切相关。在许多模型中都描述了在强制表达Myc后静止细胞进入细胞周期的情况。此外,Myc的下调或失活会导致细胞周期进程受损。鉴于Myc癌基因在人类癌症中经常失调,剖析Myc在细胞周期控制中作用的潜在机制非常重要。有几种并行机制解释了Myc介导的细胞周期刺激作用。首先,大多数关键的细胞周期正向调节因子由Myc诱导的基因编码。这些Myc靶基因包括周期蛋白依赖性激酶(Cdks)、细胞周期蛋白和E2F转录因子。除了对转录的直接影响外,Myc还能够通过诱导Cdk激活激酶(CAK)和Cdc25磷酸酶来过度激活细胞周期蛋白/Cdk复合物。此外,Myc通过不同机制拮抗细胞周期抑制剂如p21和p27的活性。因此,Myc能够阻断p21的转录或诱导参与p27降解的蛋白Skp2。最后,Myc通过结合复制起点并上调编码复制起始所需蛋白的基因来诱导DNA复制。Myc还调节参与有丝分裂控制的基因。一种基于抑制Cdks的合成致死性是治疗Myc失调肿瘤的一种有前景的方法。因此,了解Myc依赖的细胞周期调节机制将有助于发现针对Myc失调恶性肿瘤的新治疗方法。本文是名为:细胞生物学和病理学中的Myc蛋白的特刊的一部分。